Pharma
Glenmark Pharmaceuticals Ltd
GLENMARK · NSE · INE935A01035Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE14.1%
ROCE14.7%
ROE14.1%
1Y Return+14.01%
Avg. Volume0.5M
Price Chart
About
Glenmark Pharmaceuticals Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price—
52W High / Low—
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE14.1%
1Y Return+14.01%
Day Change—
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹17,737 Cr | ₹16,983 Cr | ₹13,322 Cr | ||||||||||
| Expenses | ₹12,940 Cr | ₹12,410 Cr | ₹10,970 Cr | ||||||||||
| Operating Profit | ₹4,797 Cr | ₹4,572 Cr | ₹2,351 Cr | ||||||||||
| OPM % | 27.0% | 27.0% | 18.0% | ||||||||||
| Other Income | ₹-1,443 Cr | ₹-1,805 Cr | ₹-259 Cr | ||||||||||
| Depreciation | ₹617 Cr | ₹573 Cr | ₹486 Cr | ||||||||||
| Interest | ₹204 Cr | ₹209 Cr | ₹207 Cr | ||||||||||
| Profit Before Tax | ₹2,533 Cr | ₹1,985 Cr | ₹1,399 Cr | ||||||||||
| Tax | ₹735 Cr | ₹623 Cr | ₹352 Cr | ||||||||||
| Net Profit | ₹1,798 Cr | ₹1,362 Cr | ₹1,047 Cr | ||||||||||
| EPS (₹) | 63.7 | 48.3 | 37.1 | ||||||||||
| Dividend Payout % | — | 10% | 7% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,018 Cr | ₹3,771 Cr | ₹3,901 Cr | ₹6,047 Cr | |||||||||
| Expenses | ₹3,214 Cr | ₹3,008 Cr | ₹3,031 Cr | ₹3,687 Cr | |||||||||
| Operating Profit | ₹805 Cr | ₹763 Cr | ₹870 Cr | ₹2,360 Cr | |||||||||
| OPM % | 20.0% | 20.0% | 22.0% | 39.0% | |||||||||
| Depreciation | ₹173 Cr | ₹148 Cr | ₹154 Cr | ₹141 Cr | |||||||||
| Interest | ₹54 Cr | ₹43 Cr | ₹41 Cr | ₹66 Cr | |||||||||
| Net Profit | ₹483 Cr | ₹301 Cr | ₹403 Cr | ₹610 Cr | |||||||||
| EPS (₹) | 17.1 | 10.7 | 14.3 | 21.6 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹28 Cr | ₹28 Cr | ₹28 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹10,484 Cr | ₹8,821 Cr | ₹7,820 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹594 Cr | ₹2,473 Cr | ₹1,231 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹8,801 Cr | ₹4,669 Cr | ₹5,279 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹19,907 Cr | ₹15,991 Cr | ₹14,358 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹5,915 Cr | ₹4,487 Cr | ₹4,210 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹42 Cr | ₹56 Cr | ₹790 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹13,041 Cr | ₹10,613 Cr | ₹8,697 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹19,907 Cr | ₹15,991 Cr | ₹14,358 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹3,445 Cr | ₹-1,237 Cr | ₹-2,709 Cr | ₹-501 Cr |
| FY25 | ₹-828 Cr | ₹58 Cr | ₹787 Cr | ₹17 Cr |
| FY24 | ₹-265 Cr | ₹4,387 Cr | ₹-3,906 Cr | ₹215 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| 3B BlackBio Dx Ltd | ₹1,210 Cr | 21.4 | +20.2% | +17.9% |
| Aarey Drugs & Pharmaceuticals Ltd | — | — | +2.75% | +59.84% |
| Aarti Drugs Ltd | ₹3,429 Cr | 18.0 | +13.37% | +11.57% |
| Aarti Pharmalabs Ltd | ₹7,495 Cr | 35.2 | +8.51% | +14.26% |
| Abbott India Ltd | — | — | +34.46% | -7.16% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-21Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE Filing2026-09-10Glenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.PR Newswire2026-08-03Glenmark Pharmaceuticals Ltd (BOM:532296) (Q1 2027) Earnings Call Highlights: Strong 23% ...GuruFocus.com2026-07-28Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose VialsPR Newswire2026-06-11Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner GlenmarkTMX Newsfile
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.